FDA Sets New Fees for OTC Drug Facilities in 2025
Published Date: 3/21/2025
Notice
Summary
The FDA is setting new fees for facilities that make over-the-counter (OTC) drugs for fiscal year 2025. If you make or submit requests for these OTC drugs, you’ll need to pay updated fees starting October 1, 2024. These fees help the FDA keep OTC drugs safe and effective for everyone.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
OTC manufacturer facility fees start Oct 1
If you manufacture over-the-counter (OTC) monograph drugs, you must pay new OTC monograph drug facility (MDF) fees for fiscal year 2025 starting October 1, 2024. The FDA is publishing these FY2025 facility fee rates under the OTC Monograph Drug User Fee Program (OMUFA) and will assess them from qualifying manufacturers as authorized by the FD&C Act.
Submitters of OMORs must pay FY2025 fees
If you submit OTC monograph order requests (OMORs), you must pay user fees under the FY2025 OMUFA facility fee rates beginning October 1, 2024. The FDA will assess and collect these fees from OMOR submitters as authorized by the Federal Food, Drug, and Cosmetic Act.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
Previous / Next Documents
Previous: 2025-04859, Environmental Impact Statements; Notice of Availability
The EPA just shared new Environmental Impact Statements (EIS) for public review, covering projects like a Texas railroad and Wyoming development plans. If you care about how these projects affect the environment, now’s the time to speak up before the comment deadlines in May and June. This helps keep communities informed and ensures projects consider nature and health before moving forward.
Next: 2025-04861, Draft 2024 Marine Mammal Stock Assessment Reports
The 2024 draft reports update the health and numbers of marine mammals in Alaska, Atlantic, and Pacific waters. These updates help protect whales, seals, and other sea creatures by using the latest info. NMFS wants your thoughts and any new data before finalizing the reports, so speak up soon!